Oculis raises $20.3m Series B round to advance treatment for Ophthalmic Diseases

Oculis, an Icelandic life sciences company, just announced a $20.3m (20m CHF) series B round led by a syndicate of leading life science venture funds including Bay … Continue reading Oculis raises $20.3m Series B round to advance treatment for Ophthalmic Diseases